Search

Your search keyword '"Schaafsma, Ron"' showing total 16 results
Start Over Author "Schaafsma, Ron"
16 results on '"Schaafsma, Ron"'

1. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

Author

van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C, Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A, Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K, Delforge, Michel, Levin, Mark-David, Bos, Gerard M, Jie, Kon-Siong G, Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G, Zweegman, Sonja, Sonneveld, Pieter, and Lokhorst, Henk M

Published
2018
Full Text
View/download PDF

2. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Author

Löwenberg, Bob, Beck, Joachim, Graux, Carlos, van Putten, Wim, Schouten, Harry C., Verdonck, Leo F., Ferrant, Augustin, Sonneveld, Pieter, Jongen-Lavrencic, Mojca, von Lilienfeld-Toal, Marie, Biemond, Bart J., Vellenga, Edo, Breems, Dimitri, de Muijnck, Hilde, Schaafsma, Ron, Verhoef, Gregor, Döhner, Hartmut, Gratwohl, Alois, Pabst, Thomas, Ossenkoppele, Gert J., Maertens, Johan, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German Austrian AML Study Group (AMLSG), and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)

Published
2010
Full Text
View/download PDF

3. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Author

Lokhorst, Henk M., van der Holt, Bronno, Zweegman, Sonja, Vellenga, Edo, Croockewit, Sandra, van Oers, Marinus H., von dem Borne, Peter, Wijermans, Pierre, Schaafsma, Ron, de Weerdt, Okke, Wittebol, Shulamiet, Delforge, Michel, Berenschot, Henriëtte, Bos, Gerard M., Jie, Kon-Siong G., Sinnige, Harm, van Marwijk-Kooy, Marinus, Joosten, Peter, Minnema, Monique C., van Ammerlaan, Rianne, and Sonneveld, Pieter

Published
2010
Full Text
View/download PDF

5. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

Author

van der Helm, Lieke H., Alhan, Canan, Wijermans, Pierre W., van Marwijk Kooy, Marinus, Schaafsma, Ron, Biemond, Bart J., Beeker, Aart, Hoogendoorn, Mels, van Rees, Bastiaan P., de Weerdt, Okke, Wegman, Jurgen, Libourel, Ward J., Luykx-de Bakker, Sylvia A., Minnema, Monique C., Brouwer, Rolf E., Croon-de Boer, Fransien, Eefting, Matthijs, Jie, Kon-Siong G., van de Loosdrecht, Arjan A., Koedam, Jan, Veeger, Nic J. G. M, Vellenga, Edo, and Huls, Gerwin

Published
2011
Full Text
View/download PDF

6. Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Author

Scheid, Christof, primary, Lokhorst, Henk, additional, Blau, Igor W, additional, Van Der Holt, Bronno, additional, Bertsch, Uta, additional, Zweegman, Sonja, additional, Weisel, Katja, additional, Vellenga, Edo, additional, Kersten, Marie José, additional, Croockewit, Sandra, additional, Mai, Elias K, additional, Raymakers, Reinier, additional, Hose, Dirk, additional, Jauch, Anna, additional, Hillengass, Jens, additional, Stevens-Kroef, Marian, additional, Raab, Marc S, additional, Neben, Kai, additional, Stilgenbauer, Stephan, additional, Broyl, Annemiek, additional, Lindemann, Hans-Walter, additional, Bos, Gerard, additional, Brossart, Peter, additional, van Marwijk Kooij, Marinus, additional, Ypma, Paula F, additional, Dührsen, Ulrich, additional, Schaafsma, Ron, additional, Hielscher, Thomas, additional, Salwender, Hans, additional, Goldschmidt, Hartmut, additional, and Sonneveld, Pieter, additional

Published
2019
Full Text
View/download PDF

8. Improved Survival with Thalidomide Before and after Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: Long-Term Results from the HOVON-50 Study

Author

van de Donk, Niels, primary, van der Holt, Bronno, additional, Minnema, Monique C., additional, Vellenga, Edo, additional, Croockewit, Sandra, additional, Kersten, Marie José, additional, von dem Borne, Peter A., additional, Ypma, Paula, additional, Schaafsma, Ron, additional, de Weerdt, Okke, additional, Klein, Saskia K., additional, Delforge, Michel, additional, Levin, Mark-David, additional, Bos, Gerard M., additional, Jie, Kon-Siong G., additional, Sinnige, Harm, additional, Coenen, Jules L.L.M., additional, de Waal, Esther G., additional, Zweegman, Sonja, additional, Sonneveld, Pieter, additional, and Lokhorst, Henk M., additional

Published
2018
Full Text
View/download PDF

9. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

Author

Gay, Francesca, primary, Larocca, Alessandra, additional, Wijermans, Pierre, additional, Cavallo, Federica, additional, Rossi, Davide, additional, Schaafsma, Ron, additional, Genuardi, Mariella, additional, Romano, Alessandra, additional, Liberati, Anna Marina, additional, Siniscalchi, Agostina, additional, Petrucci, Maria T., additional, Nozzoli, Chiara, additional, Patriarca, Francesca, additional, Offidani, Massimo, additional, Ria, Roberto, additional, Omedè, Paola, additional, Bruno, Benedetto, additional, Passera, Roberto, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Sonneveld, Pieter, additional, and Palumbo, Antonio, additional

Published
2011
Full Text
View/download PDF

10. Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Randomized Phase III Study HOVON 24 MM.

Author

Sonneveld, Pieter, primary, van der Holt, Bronno, additional, Segeren, Christine, additional, Vellenga, Edo, additional, Raymakers, Reinier, additional, Verhoef, Gregor, additional, Schaafsma, Ron, additional, van Oers, Marinus, additional, Weijermans, Pierre, additional, Fibbe, Wim, additional, Wittebol, Shulamit, additional, van Marwijk, Marinus, additional, Biesma, Douwe, additional, Baars, Joke, additional, Schouten, Harry, additional, Westveer, Petra, additional, Steijaert, Monique, additional, and Lokhorst, Henk, additional

Published
2004
Full Text
View/download PDF

11. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Author

Vellenga, Edo, van Putten, Wim, Ossenkoppele, Gert J., Verdonck, Leo F., Theobald, Matthias, Cornelissen, Jan J., Huijgens, Peter C., Maertens, Johan, Gratwohl, Alois, Schaafsma, Ron, Schanz, Urs, Graux, Carlos, Schouten, Harry C., Ferrant, Augustin, Bargetzi, Mario, Fey, Martin F., and Löwenberg, Bob

Abstract

We report the results of a prospective, randomized phase 3 trial evaluating autologous peripheral blood stem cell transplantation (ASCT) versus intensive consolidation chemotherapy in newly diagnosed AML patients in complete remission (CR1). Patients with AML (16-60 years) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high-dose cyclophosphamide and busulfan. Of patients randomized (chemotherapy, n = 259; ASCT, n = 258), more than 90% received their assigned treatment. The 2 groups were comparable with regard to prognostic factors. The ASCT group showed a markedly reduced relapse rate (58% vs 70%, P= .02) and better relapse-free survival at 5 years (38% vs 29%, P= .065, hazard ratio = 0.82; 95% confidence interval, 0.66-1.1) with nonrelapse mortality of 4% versus 1% in the chemotherapy arm (P= .02). Overall survival was similar (44% vs 41% at 5 years, P= .86) because of more opportunities for salvage with second-line chemotherapy and stem cell transplantation in patients relapsing on the chemotherapy arm. This large study shows a relapse advantage for ASCT as postremission therapy but similar survival because more relapsing patients on the chemotherapy arm were salvaged with a late transplantation for relapse. This trial is registered at www.trialregister.nlas #NTR230 and #NTR291.

Published
2011
Full Text
View/download PDF

13. Optimising pharmacotherapy in older cancer patients with polypharmacy.

Author

Vrijkorte, Elze, Vries, Jennifer, Schaafsma, Ron, Wymenga, Machteld, and Oude Munnink, Thijs

Subjects
ANTINEOPLASTIC agents, PREVENTION of drug side effects, ELDER care, GERIATRIC assessment, CANCER patients, FISHER exact test, LIFE expectancy, LONGITUDINAL method, RESEARCH, RESEARCH funding, TUMORS, POLYPHARMACY, DATA analysis software, DESCRIPTIVE statistics, INAPPROPRIATE prescribing (Medicine), OLD age
Abstract

Objective: Polypharmacy is frequent among older cancer patients and increases the risk of potential drug‐related problems (DRPs). DRPs are associated with adverse drug events, drug‐drug interactions and hospitalisations. Since no standardised polypharmacy assessment methods for oncology patients exist, we aimed to develop one that can be integrated into routine care. Methods: Based on the Systematic Tool to Reduce Inappropriate Prescribing (STRIP), we developed OncoSTRIP, which includes a polypharmacy anamnesis, a concise geriatric assessment, a polypharmacy analysis taking life expectancy into account and an optimised treatment plan. Patients ≥65 years with ≥5 chronic drugs visiting our outpatient oncology clinic were eligible for the polypharmacy assessment. Results: OncoSTRIP was integrated into routine care of our older cancer patients. In 47 of 60 patients (78%), potential DRPs (n = 101) were found. In total, 85 optimisations were recommended, with an acceptance rate of 41%. It was possible to reduce the number of potential DRPs by 41% and the number of patients with at least one potential DRP by 30%. Mean time spent per patient was 71 min. Conclusions: Polypharmacy assessment of older cancer patients identifies many pharmacotherapeutic optimisations. With OncoSTRIP, polypharmacy assessments can be integrated into routine care. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

14. Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Author

Kater, Arnon P., Van Oers, Marinus H.J. H.J., Norden, Yvette, Liu, Roberto D., Schipperus, Martin R., Chamuleau, Martine, Nijland, Marcel, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, Croon-de Boer, Fransien, Wittebol, Shulamit, Kerst, Martijn, Marijt, Willem, Posthuma, Ward, Raymakers, Reinier, Schaafsma, Ron, Dobber, Johan, Kersting, Sabina, and Levin, Mark-David

Abstract

Introduction.Since publication of the pivotal CLL011 phase 3 trial, combination of chlorambucil and anti-CD20 MAb has become the standard first-line CLL treatment for patients unfit for FCR. Lenalidomide (Len) has been proven effective both as monotherapy and in combination with rituximab. Although recent studies in CLL suggest that Len is mostly beneficial as consolidation treatment, the exact place and duration of this drug is still not optimized. Moreover, Len has shown a distinct and more difficult to manage toxicity profile in the context of CLL, potentially hampering combination treatment with this drug. We therefore conducted a phase 2 study to evaluate efficacy and safety of a combination of chlorambucil, rituximab and individual dosed Len (induction-I) followed by 6 months of Len monotherapy (induction-II).

Published
2017
Full Text
View/download PDF

15. [Autologous stem cell transplantation in haematological disorders,1980-2002].

Author

Beckers MM, Verdonck LF, Cornelissen JJ, Schattenberg AV, Janssen JJ, Willemze R, van Imhoff GW, van der Lelie JH, Wijermans P, Schaafsma R, Baars J, van Marwijk Kooij MR, Biesma DH, van Biezen A, Brand R, and Schouten HC

Subjects
Adolescent, Adult, Aged, Cohort Studies, Female, Humans, Lymphoma, Non-Hodgkin mortality, Lymphoma, Non-Hodgkin therapy, Male, Middle Aged, Multiple Myeloma mortality, Multiple Myeloma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Registries, Retrospective Studies, Survival Rate, Transplantation, Autologous, Young Adult, Hematologic Diseases mortality, Hematologic Diseases therapy, Hematopoietic Stem Cell Transplantation statistics & numerical data
Abstract

Objective: To describe activities in the field of autologous stem cell transplantation in haematological disorders in the Netherlands in the periods before and after 1993 (at that time blood was introduced as source of stem cells)., Design: Descriptive, retrospective cohort study., Method: Data were collected from the Netherlands Stem Cell Transplantation Registry TYPHON. Details of all transplant patients were reported to TYPHON by the individual transplantation centres. In this overview we describe the changes in transplantation-related mortality, relapse rates and survival in the periods 1 January 1980-31 December 1992 and 1 January 1980-31 December 2002., Results: The number of autologous stem cell transplantations increased almost five-fold in the period 1993-2002. Since 1993 the main indications for transplantation were multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), as well as acute myeloid leukaemia (AML), which was the main indication in the period before 1993. In the period before 1993 most relapses were observed in patients with acute lymphoblastic leukaemia (ALL) and MM, which resulted in low survival rates. After 1993 no great differences in relapse or survival rates were observed between the different disorders. The survival rates for patients with ALL improved during the last research period, especially among younger patients (< 45 years)., Conclusion: The number of autologous stem cell transplantations has increased considerably since 1993, especially in patients with MM and NHL.

Published
2010

16. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.

Author

Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, and Goldschmidt H

Subjects
Adult, Aged, Angiogenesis Inhibitors therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytarabine therapeutic use, Daunorubicin therapeutic use, Dexamethasone therapeutic use, Female, Humans, Male, Middle Aged, Remission Induction, Thioguanine therapeutic use, Treatment Outcome, Vincristine therapeutic use, Medical Oncology methods, Multiple Myeloma drug therapy, Thalidomide therapeutic use
Abstract

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results